Herzinsuffizienz – ein Modell für Multimorbidität

Abstract

Heart failure frequently is the consequence of different cardiac diseases and is associated with multiple cardiac and non-cardiac co-morbidities. It may be exemplary for multi-morbidity in the elderly, has negative impact on various organ systems and may induce further comorbidities. The following article addresses heart failure as a multisystem disorder.

Eine Herzinsuffizienz kann als Folge verschiedener kardiovaskulärer Erkrankungen auftreten. Sie ist häufig assoziiert mit weiteren Komorbiditäten und kann als Paradebeispiel für Multimorbidität im Alter gelten. Sie hat systemische Auswirkungen auf andere Organe, die zur Entwicklung weiterer Komorbiditäten beitragen. Dieser Artikel widmet sich dem Verständnis der Herzinsuffizienz als systemische Multiorganerkrankung.

Schlüsselwörter

Herzinsuffizienz - Komorbidität - Multimorbidität - Medikamenteninteraktion

Key words

heart failure - comorbidity - multimorbidity - drug interaction

• Literatur

• 1 Ponikowski P. Voors AA. Anker SD. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975
• 2 Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res 2015; 116: 1254-1268
• 3 Schwenger V. Remppis BA. Westenfeld R. et al. Dialyse- und Ultrafiltrationsverfahren bei kardiorenalem Syndrom Empfehlung der Arbeitsgemeinschaft „Herz – Niere“ der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. und der Deutschen Gesellschaft für Nephrologie e.V. Der Kardiologe. 2014
• 4 Ahmad T. Fiuzat M. Felker GM. et al. Novel biomarkers in chronic heart failure. Nat Rev Cardiol 2012; 9: 347-359
• 5 Yancy CW. Jessup M. Bozkurt B. et al. ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2016; 134: e282-e293
• 6 Zugck C. Muller A. Helms TM. et al. Health economic impact of heart failure: An analysis of the nationwide German database. Dtsch Med Wochenschr 2010; 135: 633-638
• 7 Melgaard L. Gorst-Rasmussen A. Lane DA. et al. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. JAMA 2015; 314: 1030-1038
• 8 Endres M. Heuschmann PU. Laufs U. et al. Primary prevention of stroke: blood pressure, lipids, and heart failure. Eur Heart J 2011; 32: 545-552
• 9 Adelborg K. Horvath-Puho E. Ording A. et al. Heart failure and risk of dementia: a Danish nationwide population-based cohort study. Eur J Heart Fail 2017; 19: 253-260
• 10 Homma S. Thompson JL. Pullicino PM. et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012; 366: 1859-1869
• 11 Angermann CE. Gelbrich G. Stork S. et al. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. JAMA 2016; 315: 2683-2693
• 12 Cowie MR. Woehrle H. Wegscheider K. et al. Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. N Engl J Med 2015; 373: 1095-1105
• 13 Guder G. Brenner S. Stork S. et al. Chronic obstructive pulmonary disease in heart failure: accurate diagnosis and treatment. Eur J Heart Fail 2014; 16: 1273-1282
• 14 Brenner S. Guder G. Berliner D. et al. Airway obstruction in systolic heart failure-COPD or congestion?. Int J Cardiol 2013; 168: 1910-1016
• 15 Saner FH. Heuer M. Meyer M. et al. When the heart kills the liver: acute liver failure in congestive heart failure. Eur J Med Res 2009; 14: 541-546
• 16 Swedberg K. Young JB. Anand IS. et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368: 1210-1219
• 17 Krack A. Sharma R. Figulla HR. et al. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 2005; 26: 2368-2374
• 18 Kalantar-Zadeh K. Block G. Horwich T. et al. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004; 43: 1439-1444
• 19 Levin NW. Handelman GJ. Coresh J. et al. Reverse epidemiology: a confusing, confounding, and inaccurate term. Semin Dial 2007; 20: 586-592
• 20 Tavazzi L. Maggioni AP. Marchioli R. et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-1239
• 21 Kjekshus J. Apetrei E. Barrios V. et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261